What is it? Why is it important?

A follow-up period after a monitoring Close-Out-Visit (COV) is important to resolve remaining open issues, and prepare the study for archiving.

 

The aim is to ensure that the study is prepared for a possible audit or inspection by regulatory authorities (e.g. Swissmedic) during the archiving period

 

Pending tasks are summarised in a follow-up letter or e-mail to the Site-INV, including the timeline for their resolution. Required follow-up actions are communicated to the Site-INV within 10-20 business days, or soon whenever possible.

 

The Site-INV files the follow-up letter or e-mail in the ISF. The monitor ensures a copy of the letter or e-mail is filed in the TMF.

 

What do I need to do?

As a monitor define follow-up tasks after the COV, such as:

  • Return of unused investigational product (e.g. IMP / IMD) and/or study material (e.g. lab material, technical equipment) to the study SP-INV, or destruction at the study site (e.g. based on SP-INV destruction SOP)
  • Implementation of an archiving SOP, which defines:
    • The selection of appropriate archiving premises (e.g. access restriction as well as protection from fire, humidity, and rodent damage)
    • The required filing of essential study records / documents (e.g. in the TMF or ISF)
    • How to ensure archived study records remain accessible and legible during the entire archiving period
    • The traceability of removed and returned study documents/records from the archive
  • Submission of a Clinical Study report (CSR) to the Ethics Committee (EC) and, as applicable, regulatory authorities (e.g. Swissmedic, international)
  • The update of the study in the applicable registries

Where can I get help?

Your local Research Support Centre can assist you with experienced staff regarding this topic

  • Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch

  • Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch

  • Bern, Department of Clinical Research (DCR), dcr.unibe.ch

  • Geneva, Clinical Research Center (CRC), crc.hug.ch

  • Lausanne, Clinical Research Center (CRC), chuv.ch

  • St. Gallen, Clinical Trials Unit (CTU), h-och.ch

  • Zürich, Clinical Trials Center (CTC), usz.ch

SCTO Research Tools & Resources

References

ICH GCP E6(R3) – see in particular guidelines

  • Glossary: definition monitoring
  • Glossary: definition monitoring report
  • 3.10.1.3 Risk control
  • 3.11.4 Monitoring
  • 3.11.4.5 Monitoring activities
  • 3.11.4.5.1 Communication with parties conducting the trial

ISO 14155:2026 Medical Device – see in particular section (access liable to costs)

  • 8.2 Routine close-out
  • Annex E: Essential clinical investigation documents

Swiss Law

ClinO – see in particular article

  • Art. 38 Notification upon study completion, discontinuation, or interruption
Abbreviations
  • ClinO – Clinical Trials Ordinance
  • COV – Close-Out-Visit
  • CTU – Clinical Trials Unit
  • FU – Follow-Up Letter
  • GCP – Good Clinical Practice
  • IC – Informed Consent
  • ICH GCP – International Council for Harmonisation Good Clinical Practice
  • IMD – Investigational Medical Device
  • IMP – Investigational Medicinal Product
  • ISF – Investigator Site File
  • ISO – International Organisation for Standardisation
  • SCTO – Swiss Clinical Trial Organisation
  • Site-INV – Site Investigator
  • SP-INV – Sponsor-Investigator
Completion ↦ Monitoring ↦ Close-Out Visit ↦ Follow-Up
Study
Basic

Provides some background knowledge and basic definitions

Basic Monitoring
Concept

Starts with a study idea

Ends after having assessed and evaluated study feasibility

Concept Statistic Methodology
Concept Drug or Device
Development

Starts with confidence that the study is feasible

Ends after having received ethics and regulatory approval

Development Drug or Device
Set-Up

Starts with ethics and regulatory approval

Ends after successful study initiation

Set-Up Ethics and Laws
Set-Up Statistic Methodology
Set-Up Quality and Risk
Set-Up Drug or Device
Conduct

Starts with participant recruitment

Ends after the last participant has completed the last study visit

Conduct Statistic Methodology
Conduct Drug or Device
Completion

Starts with last study visit completed

Ends after study publication and archiving

Completion Drug or Device
Current Path (click to copy): Completion ↦ Monitoring ↦ Close-Out Visit ↦ Follow-Up